摘要
目的:了解乙型肝炎病毒(HBV)感染者 HBV 基因型的构成状况及 HBV P 区基因变异的特点。方法对2010年8月~2011年10月送检的740份 HBV 感染者血清,采用 ABI 基因测序仪检测 HBV 耐药位点和基因型,应用 SPSS15.0软件进行统计分析。结果在740例 HBV 感染者中,检出 HBV B 基因型40例(5.41%),C 基因型695例(93.92%),D 基因型5例(0.68%);与拉米夫定、阿德福韦酯和恩替卡韦耐药明确相关的位点突变377例(50.95%),其中195例(51.72%)患者既往有明确的应用核苷(酸)类似物(NA)史,在这195例发生耐药的患者中,B基因型12例,C 基因型183例,两基因型间耐药发生率无明显差异,他们中包括 CHB 患者118例,肝硬化患者77例,主要耐药变异模式为 M204V+L180M、M204I、M204I+L180M 和 A181V,两组间 ALT、HBV DNA 载量和主要耐药变异模式检出率均无统计学差异;HBV DNA 载量是影响 NA 耐药的相关因素(x2=0.496,P〈0.001),但耐药与年龄、性别、疾病严重程度(CHB 或肝硬化)和 ALT 水平无显著性相关;此外,本文还检出多处未知变异位点,如 rt64、rt126、rt178和 rt129等。结论核苷(酸)类似物的使用将伴随病毒变异的发生,其耐药基因变异位点具有一定的特点及规律性,动态监测 HBV DNA 载量对早期发现耐药有一定的价值。
Objective Hepatitis B virus (HBV) genotypes and pre-core mutations were studied in patients with HBV infection. Methods Viral DNA was extracted from serum samples of 740 patients with hepatitis B and liver cirrhosis from August 2010 to October 2011,and HBV genotypes and pre-core mutations were detected by ABI sequencing instrument. Results Among 740 patients with HBV infection,40(5.41%) were with HBV genotype B,695(93.92%) were with genotype C,and 5(0.68%) were with genotype D infection;377(50.95%) patients car-ried mutations related to lamivudine,adefovir dipivoxil and entecavir resistance,among whom 195 patients(51.72%) has a definite history of application of nucleos(t)ide analog (NA). Out of the 195 patients,there were 12 patients with HBV genotype B and 183 with genotype C infection. Also among these patients with definite NA history,118 patients were with CHB,and 77 patients were with liver cirrhosis,and the major resistant mutations were M204V+L180M,M204,M204I+L180M and A181V;Serum HBV DNA load was related to NA resistance(x2=0.496, P〈0.001),but not age,gender,disease severity (CHB or cirrhosis) and ALT levels;Besides,a number of new muta-tions,e.g. rt64,rt126,rt178,rt129 and so on were found in this series. Conclusions The administration of NA might results in mutation of hepatitis B virus and drug resistance,and the mutations have certain characteristics. Dynamic monitoring of serum HBV DNA load will help early detection of gene mutation and drug resistance.
出处
《实用肝脏病杂志》
CAS
2014年第3期255-258,共4页
Journal of Practical Hepatology
基金
国家自然科学基金项目(编号:81371867)
2011年江苏省"科教兴卫"医学重点人才培养基金(编号:RC2011117)
关键词
乙型肝炎
突变
核苷(酸)类似物
耐药
Hepatitis B
Mutation
Nucleos(t)ide analog
Drug-resistant